FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Read more
Hospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants. Read more
Valeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products. Details
Click to contact the editorial team. Click to contact the sales team.
Part of the
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
